Keywords: acneiform eruption; cancer care; cutaneous toxicity; dermatitis; dupilumab; eczematous dermatitis; epidermal growth factor inhibitor; erosive pustular dermatosis; oncodermatologist; oncodermatology; pruritus; targeted therapy; toxicity.